Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016

Completed

• Conditions: Non-hodgkin Lymphoma; Acute Leukemia; Hodgkin Lymphoma; Malignant Haemopathies
• Interventions: Drug: administered therapeutic regimens

• Registration Number: NCT03469921
• Lead Sponsor: Institut Paoli-Calmettes

Brief Summary

Unicentric retrospective analysis of a cohort of 602 young adult and adolescent patients, aged 15 to 30 years, with haematological malignancies, and managed between 2000 and 2016

Detailed Description

The therapeutic results (response and survival) of young adult and adolescent patients with hematological malignancies are generally lower than those usually observed in adults over the age of 30, with equivalent treatment, particularly in lymphomatous pathology.The overall analysis of this large cohort of patients in its entirety, then by age groups (15-17 years, 18-25 years, 26-30 years) and pathology aims to describe the future of patients and patients. compare them to the results of the literature observed in this age group, and according to the therapeutic regimens administered (pediatric regimen or adult regimen).

Study Timeline

• Study Start: 2000-01-01
• Primary Completion: 2016-12-31
• Study Completion: 2016-12-31
• Status Verified: 2018-03
• Study First Submitted: 2018-03-05
• Study First Submitted QC: 2018-03-16
• Last Update Submitted: 2018-03-16
• Study First Posted: 2018-03-19
• Last Update Posted: 2018-03-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 602

Inclusion Criteria

• Malignant hemopathies (acute leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma) in primary care between 2000 and 2016.

Exclusion Criteria

• Not applicable

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patients not included in clinical trials	administered therapeutic regimens	patients not included in clinical trials
pediatric therapeutic regimen administered	administered therapeutic regimens	pediatric therapeutic regimen administered
adult therapeutic regimen administered	administered therapeutic regimens	adult therapeutic regimen administered
patients included in clinical trials	administered therapeutic regimens	patients included in clinical trials
26-30 years old	administered therapeutic regimens	26-30 years old
15-17 years old	administered therapeutic regimens	15-17 years old
non-Hodgkin's lymphoma	administered therapeutic regimens	non-Hodgkin's lymphoma
Hodgkin lymphoma	administered therapeutic regimens	Hodgkin lymphoma
18-25 years old	administered therapeutic regimens	18-25 years old
acute leukemia	administered therapeutic regimens	acute leukemia

Primary Outcome Measures

Name	Time	Method
Global Survival	15 years	delay between the date of diagnosis and the date of the latest news
Survival without event	15 years	delay between the date of diagnosis and an event (relapse, death, lost of follow-up)
Progression-free survival	15 years	defined as the delay between the date of diagnosis and the date of relapse or death.

Secondary Outcome Measures

Name	Time	Method
Epidemiological distribution by pathology compared to the adult population over 30 years	1 day	Epidemiological distribution by pathology compared to the adult population over 30 years
Descriptive analysis of the characteristics of the disease at diagnosis by pathology	15 years	Descriptive analysis of the characteristics of the disease at diagnosis by pathology
Descriptive analysis of treatments by pathology	15 years	Descriptive analysis of treatments by pathology
Overall survival (OS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology	15 years	Overall survival (OS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology
Event-free survival (EFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology	15 years	Event-free survival (EFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology
Progression-free survival (PFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology	15 years	Progression-free survival (PFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology
Long-term toxicity analysis (second cancers, fertility) for the global cohort and pathology.	15 years	Long-term toxicity analysis (second cancers, fertility) for the global cohort and pathology.

Trial Locations

Locations (1)

Institut Paoli Calmettes; 🇫🇷 Marseille, Bouches Du Rhone, France